Code intelligence

FDA-BLA125360 reimbursement alerts

Policy changes, MAC LCD updates, and CMS guidance referencing code FDA-BLA125360.

Critical code risk

Signal breakdown

1 shown · 1 total in platform

Risk: Critical

Critical

100%

High

Routine

Low

New this month

alerts added in last 30 days

Effective soon

—

no upcoming deadlines

FDA Approval: XEOMIN (INCOBOTULINUMTOXINA) — Type 1 - New Molecular Entity

Policy FDA-BLA125360 · Neurology

Critical

Xeomin (incobotulinumtoxinA) is an injectable botulinum toxin type A administered via injection, placing it squarely in the Medicare Part B pathway for physician-administered drugs. It is reimbursed u

View alert